Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
33.00
-0.65 (-1.92%)
Nov 5, 2024, 1:19 PM EST - Market open
Castle Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 36.5, with a low estimate of 25 and a high estimate of 42. The average target predicts an increase of 10.62% from the current stock price of 33.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CSTL stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 1 | 1 | 3 | 3 |
| Buy | 5 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 6 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Maintains $28 → $36 | Buy | Maintains | $28 → $36 | +9.11% | Nov 5, 2024 |
| Baird | Baird | Buy Maintains $37 → $39 | Buy | Maintains | $37 → $39 | +18.20% | Nov 5, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $35 → $42 | Strong Buy | Maintains | $35 → $42 | +27.29% | Oct 29, 2024 |
| BTIG | BTIG | Strong Buy Maintains $35 → $40 | Strong Buy | Maintains | $35 → $40 | +21.23% | Oct 14, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $37 | Buy | Reiterates | $37 | +12.14% | Aug 6, 2024 |
Financial Forecast
Revenue This Year
303.95M
from 219.79M
Increased by 38.29%
Revenue Next Year
265.85M
from 303.95M
Decreased by -12.53%
EPS This Year
-0.56
from -2.14
EPS Next Year
-2.34
from -0.56
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 322.9M | 293.5M | 351.9M | ||
| Avg | 304.0M | 265.9M | 304.9M | ||
| Low | 276.6M | 239.1M | 263.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 46.9% | -3.4% | 32.4% | ||
| Avg | 38.3% | -12.5% | 14.7% | ||
| Low | 25.8% | -21.3% | -0.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.27 | -1.29 | -0.44 | ||
| Avg | -0.56 | -2.34 | -1.43 | ||
| Low | -1.15 | -2.87 | -2.24 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.